Ezetimibe Ameliorates Early Diabetic Nephropathy in db/db Mice

  • Tamura Yukinori
    Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine. Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine.
  • Murayama Toshinori
    Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine. Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine.
  • Minami Manabu
    Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine. Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine.
  • Matsubara Takeshi
    Department of Nephrology, Kyoto University Graduate School of Medicine. Department of Nephrology, Kyoto University Graduate School of Medicine.
  • Yokode Masayuki
    Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine. Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine.
  • Arai Hidenori
    Department of Human Health Sciences, Kyoto University Graduate School of Medicine. Department of Human Health Sciences, Kyoto University Graduate School of Medicine.

Search this article

Abstract

Aim: Lipid-lowering medications have been suggested to have a potential benefit in the treatment of chronic kidney disease (CKD) such as diabetic nephropathy. Although ezetimibe has been widely used to lower serum cholesterol levels, the effect of this drug on diabetic nephropathy remains unclear. In the present study, therefore, we examined the protective effect of ezetimibe on diabetic nephropathy in db/db mice.<BR>Method: Db/db mice were fed a standard diet with 0.01% (w/w) of ezetimibe for 8 weeks from 8 weeks of age.<BR>Results: Treatment with ezetimibe did not affect food intake, body weight gain, adiposity, or blood pressure in db/db mice. Ezetimibe also had no effect on glucose metabolism such as fasting plasma glucose and insulin; however, it markedly reduced plasma lipid levels and hepatic lipid contents and reduced the urinary excretion of albumin by 50% in db/db mice, suggesting the effect of ezetimibe on diabetic nephropathy. Furthermore, ezetimibe improved glomerular hypertrophy. Although ezetimibe had no effect on oxidative stress measured by urinary 8-OHdG in db/db mice, the plasma adiponectin level was normalized, and the expression of adiponectin receptor 1 in the kidney was increased by ezetimibe treatment.<BR>Conclusion: Our data suggest that ezetimibe can improve early diabetic nephropathy through its hypolipidemic effect, and the amelioration of adiponectin resistance may also be responsible for the renoprotective effect of ezetimibe as its underlying mechanism.

Journal

Citations (2)*help

See more

References(28)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top